| Postoperative Telerehabilitation in Older Adults (NCT05435885) | Pusan National University Hospital | 2022-07-25 |
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (NCT05461430) | Travera Inc | 2022-07-15 |
| Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer (NCT05440916) | University Medical Centre Maribor | 2022-07-14 |
| A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) (NCT05460273) | AstraZeneca | 2022-07-11 |
| Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC (NCT05380271) | Gang Wu | 2022-07-01 |
| THIO Sequenced With Cemiplimab in Advanced NSCLC (NCT05208944) | Maia Biotechnology | 2022-06-08 |
| A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours (NCT05397171) | AstraZeneca | 2022-06-07 |
| Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC (NCT05163249) | Guangdong Association of Clinical Trials | 2022-05-31 |
| A Real World Study of Ensartinib in Advanced ALK-positive NSCLC (NCT05498064) | Peking Union Medical College Hospital | 2022-05-13 |
| Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer (NCT05260606) | Samsung Medical Center | 2022-05-09 |
| Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) (NCT05298423) | Merck Sharp & Dohme LLC | 2022-05-03 |
| SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer (NCT05319574) | Sun Yat-sen University | 2022-04-24 |
| Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer (NCT05306847) | Peking Union Medical College Hospital | 2022-04-01 |
| A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (NCT05241834) | Eli Lilly and Company | 2022-03-23 |
| Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (NCT05525338) | University Medical Center Groningen | 2022-03-23 |
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations (NCT05241873) | Blueprint Medicines Corporation | 2022-03-04 |
| Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC (NCT04925986) | Sarah Goldberg | 2022-02-10 |
| SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009) (NCT04527419) | Fudan University | 2022-02-09 |
| Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer (NCT04956146) | The First Affiliated Hospital with Nanjing Medical University | 2022-02-02 |
| Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation (NCT05263947) | Tianjin Medical University Cancer Institute and Hospital | 2022-01-30 |
| Predictive Assay for Decision Making in Adjuvant Therapy (NCT05032352) | Insight Molecular Diagnostics | 2022-01-28 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC (NCT05153408) | Blueprint Medicines Corporation | 2022-01-13 |
| A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors (NCT05194072) | Seagen, a wholly owned subsidiary of Pfizer | 2022-01-12 |
| A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (NCT04819100) | Eli Lilly and Company | 2021-12-20 |
| A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer (NCT05250817) | Bristol-Myers Squibb | 2021-12-09 |
| Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28) (NCT04597671) | Association NVALT Studies | 2021-12-06 |
| A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (NCT04988295) | Janssen Research & Development, LLC | 2021-11-17 |
| NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC (NCT04984811) | NeoImmuneTech | 2021-11-15 |
| Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers (NCT05099549) | NKGen Biotech, Inc. | 2021-11-03 |
| Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil (NCT04948411) | Latin American Cooperative Oncology Group | 2021-09-30 |
| Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC (NCT05167604) | Tang-Du Hospital | 2021-09-30 |
| A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer (NCT04931654) | AstraZeneca | 2021-09-28 |
| Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. (NCT04823377) | Institut Curie | 2021-09-24 |
| Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (NCT04816214) | Novartis Pharmaceuticals | 2021-09-22 |
| A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers (NCT04879849) | Takeda | 2021-09-09 |
| Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (NCT04486833) | Genprex, Inc. | 2021-09-03 |
| A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer (NCT05068024) | Forward Pharmaceuticals Co., Ltd. | 2021-08-23 |
| A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving Durvalumab (NCT04884269) | AstraZeneca | 2021-08-11 |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (NCT04956640) | Eli Lilly and Company | 2021-07-19 |
| Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab (NCT04748419) | University of Nebraska | 2021-07-15 |
| Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer (NCT04974879) | Qingdao Central Hospital | 2021-07-01 |
| A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer (NCT04611776) | Hoffmann-La Roche | 2021-07-01 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC (NCT04862780) | Blueprint Medicines Corporation | 2021-06-29 |
| Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (NCT04776447) | Fundación GECP | 2021-06-16 |
| An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC) (NCT04919616) | Shanghai OriginCell Therapeutics Co., Ltd. | 2021-06-15 |
| Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies (NCT04878692) | Hospices Civils de Lyon | 2021-06-01 |
| Drug-eluting Beads Bronchial Arterial Chemoembolization in Stage II-III Non-small-cell Lung Cancer Patients Failed, Refused or Ineligible to Receive Standard Treatments (NCT04825925) | Tianjin Medical University Cancer Institute and Hospital | 2021-05-01 |
| Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial (NCT04432142) | Maastricht Radiation Oncology | 2021-04-01 |
| Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (NCT04699188) | Novartis Pharmaceuticals | 2021-02-24 |
| Toward High Fidelity Adaptive Radiotherapy in the Thorax (NCT04731571) | Henry Ford Health System | 2021-02-05 |
| Feasibility of an Acute Physical Exercise Before Treatment Infusion for Metastatic Lung Cancer Patients (NCT04676009) | Centre Leon Berard | 2021-01-21 |
| A Study of SGN-STNV in Advanced Solid Tumors (NCT04665921) | Seagen Inc. | 2021-01-18 |
| Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations (NCT04579380) | Seagen, a wholly owned subsidiary of Pfizer | 2021-01-11 |
| A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement (NCT04543188) | Pfizer | 2021-01-08 |
| Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer (NCT05104281) | Qingdao Central Hospital | 2021-01-01 |
| A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC) (NCT04887519) | Takeda | 2020-12-30 |
| MYLUNG Consortium Study Protocol 2 (NCT05644808) | US Oncology Research | 2020-12-29 |
| A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer (NCT04794010) | Bristol-Myers Squibb | 2020-12-22 |
| Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects (NCT04515979) | MedPacto, Inc. | 2020-12-17 |
| Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer (NCT04499053) | Georgetown University | 2020-12-09 |
| External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC (NCT04697446) | Blueprint Medicines Corporation | 2020-12-01 |
| Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) (NCT04585815) | Pfizer | 2020-11-10 |
| A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (NCT04538664) | Janssen Research & Development, LLC | 2020-10-13 |
| Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy (NCT04471428) | Hoffmann-La Roche | 2020-10-01 |
| Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC) (NCT04255836) | Zhejiang Cancer Hospital | 2020-09-30 |
| A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT04487080) | Janssen Research & Development, LLC | 2020-09-30 |
| Osimertinib for NSCLC With Uncommon EGFR Mutations (NCT05421936) | Sheba Medical Center | 2020-09-27 |
| Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (NCT04427072) | Novartis Pharmaceuticals | 2020-09-25 |
| A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors (NCT04452214) | Cantargia AB | 2020-09-24 |
| A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer (NCT04426825) | Hoffmann-La Roche | 2020-09-09 |
| A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer (NCT04838548) | Shanghai Miracogen Inc. | 2020-09-04 |
| Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study (NCT04397432) | Tian Xie | 2020-08-28 |
| A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC (NCT04452877) | Novartis Pharmaceuticals | 2020-08-19 |
| Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations (NCT04323436) | Novartis Pharmaceuticals | 2020-08-19 |
| NEUWAVE Flexible Probe Study #2 (NCT03713099) | Ethicon, Inc. | 2020-07-31 |
| First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting (NCT04391283) | First Affiliated Hospital of Zhejiang University | 2020-07-27 |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT04222972) | Hoffmann-La Roche | 2020-07-24 |
| A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies (NCT04544748) | AO GENERIUM | 2020-07-22 |
| Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (NCT04385368) | AstraZeneca | 2020-07-17 |
| Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) (NCT04380636) | Merck Sharp & Dohme LLC | 2020-07-06 |
| PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study (NCT04115410) | Sungkyunkwan University | 2020-07-01 |
| Immunotherapy in Lung Cancer: Treatment After IO Cessation. (NCT04465942) | European Lung Cancer Working Party | 2020-06-26 |
| Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA) (NCT04529564) | AstraZeneca | 2020-06-12 |
| Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma (NCT04224337) | Seoul National University Hospital | 2020-06-11 |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors (NCT04389632) | Seagen, a wholly owned subsidiary of Pfizer | 2020-06-08 |
| Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations. (NCT03958565) | University of Colorado, Denver | 2020-04-28 |
| Why in Hospital After VATS Lobectomy (NCT04294108) | Rigshospitalet, Denmark | 2020-04-20 |
| A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) (NCT04194203) | Hoffmann-La Roche | 2020-04-09 |
| Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in Brazil (NCT04947683) | Latin American Cooperative Oncology Group | 2020-04-06 |
| Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases (NCT03996473) | Bayer | 2020-03-06 |
| KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) (NCT04165096) | Merck Sharp & Dohme LLC | 2020-01-21 |
| The Effect of a Combined Drainage Strategy in Uniportal Upper Lung Lobectomy (NCT04461652) | Tongji University | 2020-01-05 |
| Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT04051827) | Millennium Pharmaceuticals, Inc. | 2019-12-23 |
| KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) (NCT04165070) | Merck Sharp & Dohme LLC | 2019-12-19 |
| KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) (NCT04165798) | Merck Sharp & Dohme LLC | 2019-12-19 |
| KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) (NCT04165083) | Merck Sharp & Dohme LLC | 2019-12-19 |
| Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors (NCT03023319) | Nagla Abdel Karim | 2019-12-10 |
| A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer (NCT04025879) | Bristol-Myers Squibb | 2019-11-05 |
| A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT04075396) | Janssen Research & Development, LLC | 2019-10-16 |
| OMEGA, Local Ablative Therapy in Oligometastatic NSCLC (NCT03827577) | Azienda Ospedaliera Universitaria Integrata Verona | 2019-10-01 |